Universal Brain

Universal Brain

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Universal Brain is an early-stage neuroscience and AI company aiming to revolutionize the diagnosis and treatment of depression through objective, brain-based biomarkers. Its core platform, Neurotique™, combines a proprietary EEG headset with digital event-related potential (ERP) tasks and algorithms to subtype patients based on functional neural measures, moving beyond subjective symptom reporting. The company's initial focus is on reducing heterogeneity in clinical trials and aiding clinician decision-making, with the long-term goal of establishing a new data-driven standard in psychiatry.

PsychiatryMajor Depressive Disorder

Technology Platform

Integrated platform combining a proprietary EEG wearable, a digital ERP task interface (Neurotique™), and machine learning algorithms to subtype patients based on functional brain measures (neurotyping).

Opportunities

The massive unmet need in depression treatment and the high failure rate of CNS drug trials create a strong demand for objective stratification tools.
The platform can first generate revenue by de-risking pharmaceutical clinical trials before expanding into the larger clinical decision support market.

Risk Factors

The core scientific premise requires extensive and costly clinical validation.
The company also faces regulatory hurdles for clinical use and must overcome adoption challenges in a traditionally symptom-based field, all while navigating competition from other digital biomarker approaches.

Competitive Landscape

Competition includes other companies developing digital biomarkers for psychiatry (e.g., Alto Neuroscience using EEG & AI, Mindstrong, Karuna Health) and established clinical EEG service providers. Universal Brain differentiates with its specific focus on active ERP tasks and a defined 'neurotype' clustering approach.